Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Clinical Trials Related to Olaparib
Related studies linked through entity extraction aliases.
Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).
- Status
- COMPLETED
- Phase
- PHASE1
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations
- Status
- COMPLETED
- Phase
- PHASE2
Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
- Status
- COMPLETED
- Phase
- PHASE3
Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status
- Status
- COMPLETED
- Phase
- PHASE2
Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
- Status
- COMPLETED
- Phase
- PHASE2
The Drug Rediscovery Protocol (DRUP Trial)
- Status
- RECRUITING
- Phase
- PHASE2
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.
- Status
- COMPLETED
- Phase
- PHASE2
Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer
- Status
- UNKNOWN
- Phase
- PHASE2